Caribou Biosciences, Inc.
CRBU Healthcare Biotechnology
Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue fell 43.8%, EPS grew 58.6% and free cash flow fell 33.2%, each against the same quarter a year earlier.
Follow CRBU
Caribou Biosciences, Inc. (CRBU) EV/Sales
As of 16 October 2026, Caribou Biosciences, Inc. (CRBU) trades at a EV/Sales of −6.5×. Over the past ten years it has ranged from −14.2× (April 2025) to 80.1× (September 2021); the current reading is higher than 12% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.8× | — |
| FY2024 | −6.6× | — |
| FY2023 | 2.4× | (78.57%) |
| FY2022 | 11.1× | 4.82% |
| FY2021 | 10.6× | 256.56% |
| FY2020 | 3.0× | 0.00% |
| FY2019 | 3.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.5× | 13.21% |
| Mar 2026 | 5.8× | 602.42% |
| Dec 2025 | 0.8× | (89.13%) |
| Sep 2025 | 7.5× | — |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CRBU Caribou Biosciences, Inc. | −6.5× |
| ACET Adicet Bio, Inc. compare | −1.8× |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| ELTX Elicio Therapeutics, Inc. compare | 0.6× |
| HOWL Werewolf Therapeutics, Inc. compare | 1.9× |
| HYPD Hyperion DeFi, Inc. compare | 27.9× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)